Hypergonadotropic hypogonadism occurs when the gonads fail to respond to gonadotropins produced by the anterior pituitary gland. This is commonly seen in Turner’s syndrome, where gonadal dysgenesis leads to low sex steroid levels despite elevated levels of LH and FSH. On the other hand, hypogonadotropic hypogonadism can be caused by Kallmann syndrome, Sheehan’s syndrome, and anorexia nervosa. In Asherman’s syndrome, intrauterine adhesions develop, often due to surgery.

Understanding Infertility: Initial Investigations and Key Counselling Points

Infertility is a common issue that affects approximately 1 in 7 couples. However, it is important to note that around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

To determine the cause of infertility, basic investigations are typically conducted. These include a semen analysis and a serum progesterone test, which is done 7 days prior to the expected next period. The interpretation of the serum progesterone level is as follows: if the level is less than 16 nmol/l, it should be repeated and if it consistently remains low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

In addition to these investigations, there are key counselling points that should be addressed. These include advising the patient to take folic acid, aiming for a BMI between 20-25, and having regular sexual intercourse every 2 to 3 days. Patients should also be advised to quit smoking and limit alcohol consumption.

By understanding the initial investigations and key counselling points for infertility, healthcare professionals can provide their patients with the necessary information and support to help them conceive.

A pregnant woman who has 3 risk factors should receive LMWH from 28 weeks until 6 weeks after giving birth. If she has more than 3 risk factors, she should start LMWH immediately and continue until 6 weeks postnatal.

The risk factors for thromboprophylaxis include age over 35, a body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low risk thrombophilia, multiple pregnancy, and IVF pregnancy.

In this particular case, the woman has 4 risk factors, including being 36 years old, a smoker, having a parity over 3, and a body mass index of 33. Therefore, she needs to begin taking low molecular weight heparin immediately and continue until 6 weeks after giving birth.

While all pregnant women should be advised to stay mobile and hydrated, this woman requires medical treatment due to her increased risk factors.

Pregnancy increases the risk of developing venous thromboembolism (VTE), which is why it is important to assess a woman’s individual risk during pregnancy and take appropriate prophylactic measures. A risk assessment should be conducted at the time of booking and on any subsequent hospital admission. Women with a previous VTE history are automatically considered high risk and require low molecular weight heparin throughout the antenatal period, along with input from experts. Women at intermediate risk due to hospitalization, surgery, comorbidities, or thrombophilia should also be considered for antenatal prophylactic low molecular weight heparin.

The risk assessment at booking should include factors that increase the likelihood of developing VTE, such as age over 35, body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low-risk thrombophilia, multiple pregnancy, and IVF pregnancy. If a woman has four or more risk factors, immediate treatment with low molecular weight heparin should be initiated and continued until six weeks postnatal. If a woman has three risk factors, low molecular weight heparin should be initiated from 28 weeks and continued until six weeks postnatal.

If a diagnosis of DVT is made shortly before delivery, anticoagulation treatment should be continued for at least three months, as in other patients with provoked DVTs. Low molecular weight heparin is the preferred treatment for VTE prophylaxis in pregnancy, while Direct Oral Anticoagulants (DOACs) and warfarin should be avoided. By taking these measures, the risk of developing VTE during pregnancy can be reduced.

Ectopic pregnancy is more likely to occur in women who have had pelvic inflammatory disease, which can cause damage to the tubes. Other risk factors include a history of ectopic pregnancy, the presence of an intrauterine contraceptive device, endometriosis, and undergoing in-vitro fertilization. However, the use of antibiotics, condoms, and being young are not considered established risk factors. While endometriosis can increase the risk of ectopic pregnancy, this patient does not have a history of symptoms associated with the condition.

Understanding Ectopic Pregnancy: Incidence and Risk Factors

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus, usually in the fallopian tubes. This condition is a serious medical emergency that requires immediate attention. According to epidemiological studies, ectopic pregnancy occurs in approximately 0.5% of all pregnancies.

Several risk factors can increase the likelihood of ectopic pregnancy. These include damage to the fallopian tubes due to pelvic inflammatory disease or surgery, a history of previous ectopic pregnancy, endometriosis, the use of intrauterine contraceptive devices (IUCDs), and the progesterone-only pill. In vitro fertilization (IVF) also increases the risk of ectopic pregnancy, with approximately 3% of IVF pregnancies resulting in ectopic implantation.

It is important for women to be aware of the risk factors associated with ectopic pregnancy and to seek medical attention immediately if they experience symptoms such as abdominal pain, vaginal bleeding, or shoulder pain. Early diagnosis and treatment can help prevent serious complications and improve outcomes for both the mother and the fetus.

During pregnancy, progesterone plays a crucial role in causing various changes in the body, including the relaxation of smooth muscles, which leads to a decrease in blood pressure. On the other hand, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) stimulate the release of estrogen and testosterone, which are essential for the menstrual cycle and pregnancy, but do not directly cause any significant changes.

While raised levels of estrogen in the first trimester may cause nausea and other symptoms like spider naevi, palmar erythema, and skin pigmentation, they are not responsible for pregnancy-related cardiovascular changes. Similarly, testosterone typically causes symptoms of hyperandrogenism, such as hirsutism and acne, which are not related to pregnancy but are seen in conditions like polycystic ovary syndrome.

During pregnancy, various physiological changes occur in the body, such as an increase in uterine size, cervical ectropion, increased vaginal discharge, and cardiovascular/haemodynamic changes like increased plasma volume, white cell count, platelets, ESR, cholesterol, and fibrinogen, and decreased albumin, urea, and creatinine. Progesterone-related effects, such as muscle relaxation, can cause decreased blood pressure, constipation, ureteral dilation, bladder relaxation, biliary stasis, and increased tidal volume.

Oestrogen and Progesterone: Their Sources and Functions

Oestrogen and progesterone are two important hormones in the female body. Oestrogen is primarily produced by the ovaries, but can also be produced by the placenta and blood via aromatase. Its functions include promoting the development of genitalia, causing the LH surge, and increasing hepatic synthesis of transport proteins. It also upregulates oestrogen, progesterone, and LH receptors, and is responsible for female fat distribution. On the other hand, progesterone is produced by the corpus luteum, placenta, and adrenal cortex. Its main function is to maintain the endometrium and pregnancy, as well as to thicken cervical mucous and decrease myometrial excitability. It also increases body temperature and is responsible for spiral artery development.

It is important to note that these hormones work together in regulating the menstrual cycle and preparing the body for pregnancy. Oestrogen promotes the proliferation of the endometrium, while progesterone maintains it. Without these hormones, the menstrual cycle and pregnancy would not be possible. Understanding the sources and functions of oestrogen and progesterone is crucial in diagnosing and treating hormonal imbalances and reproductive disorders.

When a cervical smear sample tests positive for high-risk HPV (hrHPV), it undergoes cytological examination to check for abnormal cellular changes that may indicate early cervical cancer. In the UK, cervical screening is offered to women between the ages of 25 and 65, with those aged 25-50 offered a smear every 3 years and those aged 50-65 offered a smear every 5 years. The aim of the screening programme is to detect cervical changes early on. HPV, a sexually transmitted virus, is present in almost all sexually active individuals, and HPV 16 or 18 is present in almost all cases of cervical cancer. If hrHPV is not detected, no further testing is required, and the patient can return to routine screening. Repeating the smear is not necessary following the presence of hrHPV, but a repeat smear may be required if the laboratory report an inadequate sample. Prior to colposcopy investigation, the sample must be positive for hrHPV and dyskaryosis.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

Breast malignancy often leads to skin dimpling and nipple retraction, which are caused by the tumour infiltrating the breast ligaments and ducts. The axillary contents are enclosed by the clavipectoral fascia, and the breast’s lymphatic drainage occurs in both the axilla and internal mammary chain. The breast is highly vascularized, with the internal mammary artery being a subclavian artery branch.

The breast is situated on a layer of pectoral fascia and is surrounded by the pectoralis major, serratus anterior, and external oblique muscles. The nerve supply to the breast comes from branches of intercostal nerves from T4-T6, while the arterial supply comes from the internal mammary (thoracic) artery, external mammary artery (laterally), anterior intercostal arteries, and thoraco-acromial artery. The breast’s venous drainage is through a superficial venous plexus to subclavian, axillary, and intercostal veins. Lymphatic drainage occurs through the axillary nodes, internal mammary chain, and other lymphatic sites such as deep cervical and supraclavicular fossa (later in disease).

The preparation for lactation involves the hormones oestrogen, progesterone, and human placental lactogen. Oestrogen promotes duct development in high concentrations, while high levels of progesterone stimulate the formation of lobules. Human placental lactogen prepares the mammary glands for lactation. The two hormones involved in stimulating lactation are prolactin and oxytocin. Prolactin causes milk secretion, while oxytocin causes contraction of the myoepithelial cells surrounding the mammary alveoli to result in milk ejection from the breast. Suckling of the baby stimulates the mechanoreceptors in the nipple, resulting in the release of both prolactin and oxytocin from the pituitary gland (anterior and posterior parts respectively).

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the baby.

There are several risk factors that increase the likelihood of shoulder dystocia, including fetal macrosomia (large baby), high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior medical assistance immediately. The McRoberts’ maneuver is often used to help deliver the baby. This involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant harm to the mother. Oxytocin administration is not effective in treating shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury or neonatal death for the baby. It is important to manage shoulder dystocia promptly and effectively to minimize these risks.

PPH, which is the loss of 500 millilitres or more of blood within 24 hours of delivery, is primarily caused by uterine atony. This occurs when the uterus fails to contract after the placenta is delivered. However, other potential causes must be ruled out through thorough clinical examination. To remember the causes of PPH, the acronym ‘the 4 Ts’ can be used: Tone (uterine atony), Tissue (retained products of conception), Trauma (to the genital tract or perineum), and Thrombin (coagulation abnormalities). This information is based on RCOG Green-top Guideline No. 52.

Postpartum Haemorrhage: Causes, Risk Factors, and Management

Postpartum haemorrhage (PPH) is a condition characterized by excessive blood loss of more than 500 ml after a vaginal delivery. It can be primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. The ABC approach is used, and bloods are taken, including group and save. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage is a serious condition that can occur after vaginal delivery. It is important to understand the causes, risk factors, and management of this condition to ensure prompt and effective treatment. Primary PPH is caused by the 4 Ts, with uterine atony being the most common cause. Risk factors for primary PPH include previous PPH, prolonged labour, and emergency Caesarean section. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to be aware of the signs and symptoms of PPH and seek medical attention immediately if they occur.

During the early stages of pregnancy, the corpus luteum is stimulated to secrete progesterone by hCG, which is produced by the syncytiotrophoblast. Pregnancy tests commonly measure hCG levels in urine. This hormone is crucial for maintaining the pregnancy until the placenta is fully developed. The trophoblast is composed of two layers: the cytotrophoblast and the syncytiotrophoblast. The hypoblast is a type of tissue that forms from the inner cell mass, while the epiblast gives rise to the three primary germ layers and extraembryonic mesoderm.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

Anatomy of the Ovarian Follicle

The ovarian follicle is a complex structure that plays a crucial role in female reproductive function. It consists of several components, including granulosa cells, the zona pellucida, the theca, the antrum, and the cumulus oophorus.

Granulosa cells are responsible for producing oestradiol, which is essential for follicular development. Once the follicle becomes the corpus luteum, granulosa lutein cells produce progesterone, which is necessary for embryo implantation. The zona pellucida is a membrane that surrounds the oocyte and contains the protein ZP3, which is responsible for sperm binding.

The theca produces androstenedione, which is converted into oestradiol by granulosa cells. The antrum is a fluid-filled portion of the follicle that marks the transition of a primary oocyte into a secondary oocyte. Finally, the cumulus oophorus is a cluster of cells surrounding the oocyte that must be penetrated by spermatozoa for fertilisation to occur.

Understanding the anatomy of the ovarian follicle is essential for understanding female reproductive function and fertility. Each component plays a unique role in the development and maturation of the oocyte, as well as in the processes of fertilisation and implantation.

Anastrozole and letrozole are medications that belong to the class of drugs known as aromatase inhibitors. These drugs are commonly used in the treatment of breast cancer as they work by reducing the production of oestrogen in the body. Aromatase is an enzyme that converts androgens into oestrogens, and these drugs inhibit this process, which typically occurs in adipose tissue.

Tamoxifen is another medication used in the treatment of breast cancer. It works by blocking oestrogen receptors in breast tissue, which reduces the growth of breast cancer cells. However, tamoxifen can activate oestrogen receptors in other parts of the body, which increases the risk of endometrial cancer.

GnRH analogues, such as goserelin, are used in the treatment of various types of cancer, including breast and prostate cancer. These drugs work by inhibiting the secretion of gonadotropins from the pituitary gland, which reduces the stimulation of the ovaries.

Trastuzumab, also known as Herceptin, is a monoclonal antibody that is used to treat HER2-positive breast cancer. This drug works by binding to HER2 receptors, which are overexpressed in some breast cancer cells, and inhibiting their growth.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

The most frequent cause of infection is Staphylococcus aureus, which typically enters through damage to the nipple areolar complex caused by the infant’s mouth.

Breast Abscess: Causes and Management

Breast abscess is a condition that commonly affects lactating women, with Staphylococcus aureus being the most common cause. The condition is characterized by the presence of a tender, fluctuant mass in the breast.

To manage breast abscess, healthcare providers may opt for either incision and drainage or needle aspiration, with the latter typically done using ultrasound. Antibiotics are also prescribed to help treat the infection.

Breast abscess can be a painful and uncomfortable condition for lactating women. However, with prompt and appropriate management, the condition can be effectively treated, allowing women to continue breastfeeding their babies without any complications.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Monozygotic twins with one chorion and two amnions are the result of division between days 4 and 8 after fertilization. This type of twinning has diamniotic, monochorionic placentation. Division between days 8 and 12 after fertilization leads to monozygotic twins with monoamniotic, monochorionic placentation, while fertilization of two separate eggs with two separate sperm results in dizygotic twins with diamniotic, dichorionic placentation. It’s important to note that division between days 4 and 8 after fertilization does not result in dizygotic twins.

Twin Pregnancies: Incidence, Types, and Complications

Twin pregnancies occur in approximately 1 out of 105 pregnancies, with the majority being dizygotic or non-identical twins. Monozygotic or identical twins, on the other hand, develop from a single ovum that has divided to form two embryos. However, monoamniotic monozygotic twins are associated with increased risks of spontaneous miscarriage, perinatal mortality rate, malformations, intrauterine growth restriction, prematurity, and twin-to-twin transfusions. The incidence of dizygotic twins is increasing due to infertility treatment, and predisposing factors include previous twins, family history, increasing maternal age, multigravida, induced ovulation, in-vitro fertilisation, and race, particularly Afro-Caribbean.

Antenatal complications of twin pregnancies include polyhydramnios, pregnancy-induced hypertension, anaemia, and antepartum haemorrhage. Fetal complications include perinatal mortality, prematurity, light-for-date babies, and malformations, especially in monozygotic twins. Labour complications may also arise, such as postpartum haemorrhage, malpresentation, cord prolapse, and entanglement.

Management of twin pregnancies involves rest, ultrasound for diagnosis and monthly checks, additional iron and folate, more antenatal care, and precautions during labour, such as having two obstetricians present. Most twins deliver by 38 weeks, and if longer, most are induced at 38-40 weeks. Overall, twin pregnancies require close monitoring and management to ensure the best possible outcomes for both mother and babies.

During pregnancy, it is common to experience pubic symphysis dysfunction due to increased ligament laxity caused by hormonal changes. This can result in pain over the pubic symphysis that may radiate to the groins and inner thighs. It is important to differentiate this from more serious conditions such as cauda equina syndrome, which is a surgical emergency and presents with low back pain, leg pain, numbness around the anus, and loss of bowel or bladder control. While slipped lumbar vertebrae can also cause similar symptoms, it is less common than pubic symphysis dysfunction during pregnancy. Ultrasound scans can confirm a normal fetus, ruling out ectopic pregnancy and miscarriage as potential causes of the symptoms.

Understanding Symphysis Pubis Dysfunction in Pregnancy

Symphysis pubis dysfunction (SPD), also known as pelvic girdle pain, is a common condition experienced by pregnant women. It is caused by the hormone relaxin, which affects the laxity of ligaments in the pelvic girdle and other parts of the body. This increased laxity can result in pain and instability in the symphysis pubis joint and/or sacroiliac joint. Around 20% of women suffer from SPD by 33 weeks of gestation, and it can occur at any time during pregnancy or in the postnatal period.

Multiple risk factors have been identified, including a previous history of low back pain, multiparity, previous trauma to the back or pelvis, heavy workload, higher levels of stress, and job dissatisfaction. Patients typically present with discomfort and pain in the suprapubic or low back area, which may radiate to the upper thighs and perineum. Pain can range from mild to severe and is often exacerbated by walking, climbing stairs, turning in bed, standing on one leg, or weight-bearing activities.

Physical examination may reveal tenderness of the symphysis pubis and/or sacroiliac joint, pain on hip abduction, pain at the symphysis when standing on one leg, and a waddling gait. Positive Faber and active straight leg raise tests, as well as palpation of the anterior surface of the symphysis pubis, can also indicate SPD. Imaging, such as ultrasound or MRI, is necessary to confirm separation of the symphysis pubis.

Conservative management with physiotherapy is the primary treatment for SPD. Understanding the risk factors and symptoms of SPD can help healthcare providers provide appropriate care and support for pregnant women experiencing this condition.

Shoulder dystocia is the labour complication discussed in this case, and it is more likely to occur in cases of foetal macrosomia. This is because larger babies have a greater shoulder diameter, making it more difficult for the shoulders to pass through the pelvic outlet.

Maternal pre-eclampsia is a risk factor for small for gestational age (SGA) pregnancies, but it is not directly linked to shoulder dystocia.

Obstetric cholestasis is a liver disorder that can occur during pregnancy, but it does not increase the risk of shoulder dystocia.

While a previous caesarean section may increase the likelihood of placenta praevia, placenta accreta, or uterine rupture, it is not a direct risk factor for shoulder dystocia.

A previous post-term delivery may increase the likelihood of future post-term deliveries, but it does not directly increase the risk of shoulder dystocia.

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the baby.

There are several risk factors that increase the likelihood of shoulder dystocia, including fetal macrosomia (large baby), high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior medical assistance immediately. The McRoberts’ maneuver is often used to help deliver the baby. This involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant harm to the mother. Oxytocin administration is not effective in treating shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury or neonatal death for the baby. It is important to manage shoulder dystocia promptly and effectively to minimize these risks.

Anastrozole and letrozole are medications that inhibit the production of oestrogen in peripheral tissues through the enzyme aromatase. These drugs are commonly used to treat breast cancer in postmenopausal women.

Trastuzumab is a monoclonal antibody that targets HER2 receptors on cancer cells, inhibiting their growth and proliferation. It is effective in treating HER2-positive breast cancer.

Fulvestrant is a selective oestrogen receptor degrader that breaks down oestrogen receptors without activating them, unlike tamoxifen. This leads to downregulation of the receptor.

Goserelin is an LHRH agonist that suppresses oestrogen production by the ovaries. It is often used as adjuvant therapy in premenopausal women.

Tamoxifen is an antagonist (and partial agonist) of the oestrogen receptor. It is particularly useful in treating oestrogen-receptor positive breast cancer, especially in patients who have not yet gone through menopause.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

The RCGP curriculum mandates the capability to converse with patients about NHS screening programmes, as part of the objective to promote health and prevent disease. Over-diagnosis and over-treatment are the primary concerns associated with breast cancer screening. Research suggests that for every life saved by the screening programme, three women will receive treatment for a cancer that would not have posed a threat to their lives. Therefore, it is the woman’s personal decision to weigh the benefits against the risks when invited for routine screening.

Breast Cancer Screening and Familial Risk Factors

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme, with mammograms offered every three years. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually. Women over 70 years may still have mammograms but are encouraged to make their own appointments.

For those with familial risk factors, NICE guidelines recommend referral to a breast clinic for further assessment. Those with one first-degree or second-degree relative diagnosed with breast cancer do not need referral unless certain factors are present in the family history, such as early age of diagnosis, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, or complicated patterns of multiple cancers at a young age. Women with an increased risk of breast cancer due to family history may be offered screening from a younger age.

LH binds to LH receptors on thecal cells, stimulating the production of androstenedione. This androgen is then converted into oestradiol by aromatase in the granulosa cells.

The process of follicle development can be divided into several stages. Primordial follicles contain an oocyte and granulosa cells. Primary follicles are characterized by the development of the zona pellucida and proliferation of granulosa cells. Pre-antral follicles develop a theca layer. Mature or Graafian follicles are marked by the presence of an antrum. Finally, the corpus luteum forms after the oocyte is released due to enzymatic breakdown of the follicular wall.

It is important to note that FSH, progesterone, testosterone, and oestrogen receptors are not involved in the production of oestradiol from androstenedione.

Anatomy of the Ovarian Follicle

The ovarian follicle is a complex structure that plays a crucial role in female reproductive function. It consists of several components, including granulosa cells, the zona pellucida, the theca, the antrum, and the cumulus oophorus.

Granulosa cells are responsible for producing oestradiol, which is essential for follicular development. Once the follicle becomes the corpus luteum, granulosa lutein cells produce progesterone, which is necessary for embryo implantation. The zona pellucida is a membrane that surrounds the oocyte and contains the protein ZP3, which is responsible for sperm binding.

The theca produces androstenedione, which is converted into oestradiol by granulosa cells. The antrum is a fluid-filled portion of the follicle that marks the transition of a primary oocyte into a secondary oocyte. Finally, the cumulus oophorus is a cluster of cells surrounding the oocyte that must be penetrated by spermatozoa for fertilisation to occur.

Understanding the anatomy of the ovarian follicle is essential for understanding female reproductive function and fertility. Each component plays a unique role in the development and maturation of the oocyte, as well as in the processes of fertilisation and implantation.

The patient is exhibiting symptoms that are indicative of pre-eclampsia, such as headache, abdominal pain, and blurred vision. However, the presence of jaundice suggests that the patient is actually suffering from HELLP syndrome, which is a complication during pregnancy that involves haemolysis, elevated liver enzymes, and low platelets. This condition often occurs in conjunction with pregnancy-induced hypertension or pre-eclampsia.

Pre-eclampsia is a pregnancy-related disorder that is characterized by high blood pressure and damage to another organ system, typically the kidneys, which is evidenced by proteinuria. This condition typically develops after the 20th week of pregnancy in women who previously had normal blood pressure.

Jaundice During Pregnancy

During pregnancy, jaundice can occur due to various reasons. One of the most common liver diseases during pregnancy is intrahepatic cholestasis of pregnancy, which affects around 1% of pregnancies and is usually seen in the third trimester. Symptoms include itching, especially in the palms and soles, and raised bilirubin levels. Ursodeoxycholic acid is used for symptomatic relief, and women are typically induced at 37 weeks. However, this condition can increase the risk of stillbirth.

Acute fatty liver of pregnancy is a rare complication that can occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea, vomiting, headache, jaundice, and hypoglycemia. ALT levels are typically elevated. Supportive care is the initial management, and delivery is the definitive management once the patient is stabilized.

Gilbert’s and Dubin-Johnson syndrome may also be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for Haemolysis, Elevated Liver enzymes, Low Platelets, can also cause jaundice during pregnancy. It is important to monitor liver function tests and seek medical attention if any symptoms of jaundice occur during pregnancy.